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Abstract 
Objectives: To apply a systems pathology‑based approach to the quantification of nuclear Active β‑catenin and 
human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients.
Results: The systems pathology approach applied allows a precise quantification of the marker expression in the 
different cell compartments as well as the determination of the areas that coexpress two markers. Our data shows 
that the accumulation of β‑catenin in the nuclear compartment is significantly decreased in the adjacent normal 
areas when compared to tumor of the same patients (p < 0.001). In conclusion, the application of this novel multiple 
immunofluorescence assay demonstrates that the upregulation of Active β‑catenin is a relatively common feature of 
prostate tumor development, and further supports the activation of the Wnt/β‑catenin pathway in prostate cancer 
progression.
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Introduction
The origin of the data is a summary of single observa-
tions derived from a more comprehensive study encom-
passing seven protein biomarkers that were assembled 
in two multiplex assays and applied to a cohort of pros-
tate cancer patients (n = 505). Quantitative and cellular 
attributes representing biomarkers from both multiplex 
assays containing Active β-catenin (ABC), HLA-1 and 
CK18, among others, were correlated with clinical vari-
ables including biochemical recurrence (BCR). One of 
the objectives of the comprehensive work (manuscript 
in preparation) was to describe correlations between 
clinicopathological data and results from the quantifica-
tion and colocalization of individual marker expressions. 
When we started analyzing the data we observed that 
the expression of Active β-catenin was higher in tumor 
areas than in adjacent normal tissue. In this research 
note we describe for the first time how a systems biology-
based methodology yields a precise quantification of the 
nuclear Active β-catenin (effector fraction) and thus une-
quivocally demonstrates the implication of this marker in 
prostate tumor formation.
Prostate cancer is the most common epithelial malig-
nancy after skin cancer in men from western countries 
[1]. Systems pathology is a multidisciplinary approach 
that integrates proteomic, molecular and imaging data 
with the patients’ clinical history using machine learn-
ing [2]. By applying multiplex immunofluorescence and 
image analysis, we have been able to construct quantita-
tive features for interrogating several biomarkers at the 
microscopic cellular level. This allows for investigations 
of co-localization and expression of cellular proteins, 
specifically during activation of specific signaling path-
ways. Of paramount importance, the colocalization of a 
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given marker with DAPI can be applied in the quantifica-
tion of the marker that is present within the nucleus [3].
HLA class I expression on the cell surface of cancer 
cells is critical for an appropriate anti-tumor immune 
response by presenting antigenic peptides to cytotoxic T 
lymphocytes [4]. One of the most frequent escape mech-
anisms that tumor cells develop to avoid immune system 
recognition is the loss of HLA-1 expression, which corre-
lates with properties associated with ‘stemness’ resulting 
in treatment resistance and a poor prognosis [5].
The Wnt/β-catenin signaling pathway is an evolution-
arily conserved developmental pathway involved in sev-
eral physiological processes [6]. Aberrant activation of 
the Wnt/β-catenin pathway is implicated in many tumor 
types. β-catenin, a key protein in the Wnt pathway, can 
trigger the transcription of important regulators of cell 
cycle progression, cell proliferation and cell stemness 
upon activation and nuclear translocation [7]. β-catenin 
expression has been shown to be associated with more 
malignant, high Gleason score tumors. Both β-catenin 
and wnt-1 expressions are located in the advancing 
edge of the tumor [8]. The correlation between higher 
malignancy related to castrate resistant prostate cancer 
(CRPC) and β-catenin suggests Wnt/β-catenin signaling 
pathway upregulation in CRPC [6]. Here we demonstrate 
the association between nuclear localization of Active 
β-catenin and prostate tumor progression.
Main text
Materials and methods
Patient selection and TMA production
Prostate cancer samples were obtained from 505 patients 
(age  range 40–75, median 63  years)  with localized 
and locally advanced disease that underwent a radical 
prostatectomy (Hospital de la Vall d’Hebron, Hospital 
Clínic de Barcelona and Hospital 12 de Octubre). The 
Gleason  breakdown of the tumors  was as follows:  81 
tumors  Gleason < 6, 130 tumors  Gleason  6, 293 tumors 
Gleason > 6. Whole tissue sections from each patient 
were first stained and three tumor cores and a normal 
core previously selected were included in tissue microar-
rays (TMAs). Blank 3.5 µM thick consecutive sections of 
the TMA were used for IF analysis.
Multiplex setup
An Immunofluorescent (IF) multiplex reaction was 
assembled for the study of the following biomarkers: 
Active β-catenin (ABC), HLA-1 and CK18, described in 
Table  1, along with the nuclear dye, DAPI (4′,6-diamid-
ino-2-phenylindole, dilactate). CK18 was included 
to help identify epithelial cells and obtain colocaliza-
tion values with the other markers. HLA-1 is a member 
of the HLA system, a cell surface protein family that is 
responsible for the regulation of the immune system in 
humans (human leukocyte antigen class I). HLA-1 down-
regulation is associated with stemness in multiple cancer 
types [9]. β-catenin Active forms were detected with the 
mouse monoclonal clone 8E7. Prior to multiplex assem-
bly, individual IF conditions were tested, with selection of 
the optimal antibody-fluorochrome for each biomarker. 
The construction of the multiplex required a common 
heat-induced epitope retrieval (HIER) strategy that 
incorporated the use of a pH9 solution in a decloaking 
chamber at 120 °C for 3 min. After HIER, antibodies and 
Zenons (invitrogen) were added in two addition steps, 
first HLA-1 combined with ABC, and then CK18. Image 
acquisition was performed within 48 h. The immunofluo-
rescent multiplex reaction was first analyzed using appro-
priate cell-line and tissue positive controls. A series of 
reproducibility experiments were carried out prior to the 
final conditions applied to the TMA. These setup experi-
ments were used to select the optimal conditions for 
the image acquisition, as the best filter combination and 
exposition time for each of the filters. The imaging system 
included a multispectral camera (Perkin Elmer) attached 
to a 90i Nikon epifluorescent microscope with an autom-
atized stage controlled by the compatible  metamorph® 
software (Molecular Devices). Multispectral images were 
acquired at 20× magnification with the Nuance imaging 
system using the selected filter combination and expo-
sition time, and analyzed with the  Nuance® software to 
unmix and quantify individual biomarker expressions, as 
well as determining biomarker co-localization in selected 
regions within each core. The individual expression of 
each marker is obtained as the result of the quantification 
of positive pixels for the marker that are included in the 
tumor area. All expression and coexpression results were 
obtained as an average of up to three cores from each 
patient in the case of tumor samples, and directly from 
a single core of their normal counterpart. Statistical tests 
were performed after all values were obtained from the 
multispectral images (see “Statistical tests” subsection).
Nuclear Active β‑catenin assessment
The antibody for Active β-catenin (ABC) is able to detect 
nuclear, cytoplasmic and membranous ABC. The val-
ues for nuclear β-catenin, accounting for the effector 
Table 1 Markers included in the multiplex reaction
Antibody Vendor Catalog # Dilution Isotype Fluorochrome
HLA class 1 Abcam Ab52922 1:250 RIgG R488
Active 
β‑catenin
Upstate 05‑665 1:100 MIgG1 M555
CK18 Abcam Ab82254 1:50 MIgG1 M647
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fraction of the transcription factor, were deduced from 
the co-localization between DAPI and ABC in cells that 
were expressing CK18 (see Additional file  1: Figure S1 
for details on subcellular localization of ABC). ABC can 
be membranous, cytoplasmic and nuclear in cells with 
activation of the wnt/β-catenin pathway. To avoid any 
potential overestimation of nuclear ABC due to some 
background issue related to the cytoplasmic ABC expres-
sion a correction value was added. The correction fac-
tor, the co-localization value between CK18 and DAPI, 
is based on the fact that CK18 is only expressed both in 
membrane and in cytoplasm and should not be found in 
co-localization with DAPI. Thus, the correction factor 
should be zero in samples that are not affected by nuclear 
ABC overestimation.
Statistical tests
A Wilcoxon signed-rank test was applied to elucidate 
differences in the marker expression measures between 
tumor and adjacent normal areas.
Results and discussion
Marker expression data
The immunofluorescent images were acquired and 
unmixed with the multispectral camera software. After 
unmixing, the individual marker expression and the coex-
pression values were obtained from images as depicted 
in Fig. 1. DAPI, HLA class I, Active β-catenin and CK18 
are shown in discrete software assigned colors. DAPI was 
used as a nuclear counterstain, and its coexpression with 
a given value applied to the assessment of this marker 
nuclear fraction. The other markers show a glandular 
pattern. CK18 is very important in this assay because it 
is used to both select the glandular area and normalize 
the expression of the other two markers to CK18 expres-
sion. With this normalization, the expression of a marker 
inferred from the percentage of positive pixels in the 
fluorescent picture is referred to the amount of glandu-
lar compartment. Thus, the glandular normalization con-
tributes to a fair comparison between two images with 
discordant amounts of tumor or normal glandular areas.
HLA Class 1 in tumor formation
HLA class 1 is a critical component of the immune 
response and a candidate marker to show differences in 
expression between normal and tumor areas. HLA class 
1 downregulation in prostate cancer has been described 
in previous articles [10, 11]. HLA class 1 expression data 
was obtained from paired samples using the value for 
CK18 as a glandular normalization tool, as described in 
the previous section. Following these criteria 383 out of 
505 patients of those included in the cohort were ana-
lyzed with a Wilcoxon signed-rank test (Table  2). Our 
data shows a tendency for HLA class 1 downregula-
tion in prostate tumor samples although the p value for 
the difference between normal and tumor expressions 
is not as significant (p = 0.025) as expected according to 
the results described in previous papers [10, 11]. A more 
extensive cohort may be needed to shed more light on 
the relation between HLA class 1 downregulation and 
prostate cancer.
Active β‑catenin in tumor formation
Nuclear Active β-catenin expression was found asso-
ciated with prostate tumorigenesis according to the 
Wilcoxon signed-rank test calculation (p < 0.001). This 
correlation was obtained comparing the median values of 
normalized nuclear ABC in the tumor cores with the val-
ues of the same normalized ABC fraction in normal cores 
(n = 383 tumor-normal paired samples). The same level 
of significance (p < 0.001) was obtained when total ABC 
expression was assessed and compared in tumor cores vs. 
normal cores (Table 2).
Fig. 1 Individual markers with DAPI and multiplex assembling. 
Multiple fluorochrome labeled antibody hybridization on a prostate 
sample. Marker and DAPI expressions are shown in different colors; 
HLA class I in green, CK18 in red, ABC in yellow and DAPI in blue
Table 2 Wilcoxon signed-rank test for  paired samples 
(n = 383)
Marker Normal expression
Median [Q1; Q3]
Tumor 
expression 
Median [Q1; Q3]
p-value
Nuclear Active 
β‑catenin
2.05 [0.00; 7.12] 4.96 [0.46; 10.9] < 0.001
Total Active 
β‑catenin
0.28 [0.13; 0.58] 0.49 [0.20; 0.89] < 0.001
HLA class I 0.29 [0.10; 0.70] 0.28 [0.16; 0.50] 0.025
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In the current study, we present nuclear accumulation 
of Active β-catenin in prostate malignancy development. 
This finding is in agreement with the published litera-
ture [7, 8, 12–14]. β-catenin, a dual effector protein that 
was first described in the regulation of intracellular adhe-
sion,  is also a key nuclear signaling protein in the activa-
tion of the Wnt/β-catenin pathway. Downstream targets of 
β-catenin including c-Myc, Cyclin D1 and CD44, among 
others, are proliferation agents that are involved in onco-
genesis [15]. β-catenin signaling may play important roles 
in prostate cancer progression [7] and in the acquisition of 
tumor malignant phenotypes and the capacity for invasion 
through the induction of AR activity [13].
Interestingly, the correlation between tumor progres-
sion and nuclear Active β-catenin is also found with total 
ABC (nuclear, cytoplasmic and membranous). However, 
when average expression values are compared, the differ-
ence between tumor cores and normal cores is bigger for 
nuclear Active β-catenin than for total Active β-catenin. 
Our data further supports a role for the Wnt/β-catenin 
signaling pathway in prostate cancer formation and as a 
potential therapeutic target. Furthermore, applications 
which interrogate biomarkers at the intact tissue-cellular 
level will continue to advance our understanding of basic 
tumor biology.
Conclusions
To summarize, our multiplex-based systems pathology 
approach is a novel tool for the precise quantification of 
CK18 epithelial nuclear Active β-catenin through colo-
calization of DAPI and ABC. The additional evaluation 
of HLA provides insight into the biology underpinning 
prostate cancer progression. Thus, the use of the mul-
tiplex approach is essential for a more comprehensive 
analysis of various markers, including DAPI, HLA class I, 
Active β-catenin and CK18. Our results show a trend for 
HLA Class I downregulation, and strongly support the 
implication of Active β-catenin, both nuclear and total, in 
prostate cancer development.
Limitations
The study needs an expanded cohort of patients and a 
more robust assessment of HLA and nuclear ABC to fur-
ther characterize such discrete cell populations.
Additional file
Additional file 1: Figure S1. Subcellular localization of ABC. Magnified 
images demonstrating subcellular localization of ABC.
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